新肾脏,旧风险:肾移植后的心血管挑战
该综述指出心血管疾病仍是肾移植受者致病和死亡的首位原因,涉及传统、移植特异性及供受者相关风险因素的复杂交互。免疫抑制治疗、持续高血压、移植后糖尿病和慢性炎症等带来新挑战。现有风险分层工具和指南常未纳入移植特异性变量,多数证据来自非移植人群,亟需移植特异性心血管研究。
要点
- 心血管疾病是肾移植受者致病和死亡的首位原因。
- 免疫抑制、移植后糖尿病、持续高血压和慢性炎症增加心血管风险。
- 现有指南和风险工具未充分纳入移植特异性变量。
核心结论
- 心血管疾病仍是肾移植受者致病和死亡的首位原因。
- 亟需移植特异性心血管研究、个体化治疗策略及更多女性纳入研究。
研究设计与样本
- 综述,阐述肾移植后传统、移植特异性及供受者相关心血管风险因素的复杂交互。
主要发现
- 肾功能恢复可减少尿毒症毒素并改善心脏代谢指标。
- 免疫抑制治疗、持续高血压、移植后糖尿病和慢性炎症带来新挑战。
- 常见心血管并发症包括冠心病、心力衰竭、瓣膜病、外周动脉疾病和难治性高血压。
- 性别差异持续存在:男性心血管风险通常更高,女性相对死亡风险可能更大。
临床怎么用
- 需多学科协作,整合风险预测、预防和治疗以优化肾移植受者心血管结局。
- SGLT2抑制剂、GLP-1受体激动剂和非甾体类盐皮质激素受体拮抗剂有潜力但需在该人群进一步验证。
局限性
- 多数证据来自非移植人群,缺乏专门随机对照试验。
- 风险分层工具和指南常未纳入移植特异性变量,导致管理欠佳。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Kidney transplantation markedly improves survival and quality of life in patients with kidney failure, yet cardiovascular (CV) disease remains the leading cause of morbidity and mortality in kidney transplant recipients (KTRs). This review outlines the complex interplay of traditional, transplant-specific and recipient- and donor-related risk factors that sustain a high CV burden post-transplantation. While kidney function restoration reduces uremic toxins and improves cardiometabolic parameters, new challenges arise from immunosuppressive therapies, persistent hypertension, post-transplant diabetes mellitus and chronic inflammation. Common CV complications include coronary artery disease, heart failure, valvular disease, peripheral artery disease and refractory hypertension. Risk stratification tools and guidelines often fail to account for transplant-specific variables, resulting in suboptimal management. Although some pharmacological strategies and careful antihypertensive regimens show promise, most evidence is extrapolated from non-transplant populations due to the lack of dedicated randomized controlled trials. Emerging therapies like sodium-glucose co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists hold potential but require further validation in this population. Moreover, sex disparities persist in access to transplantation and in post-transplant outcomes, with men generally experiencing higher CV risk but women potentially facing greater relative mortality. The review underscores the urgent need for transplant-specific CV research, personalized therapeutic strategies including precision medicine and greater inclusion of women in research. Optimizing CV outcomes in KTRs will require multidisciplinary collaboration, rigorous evidence generation, and an integrated approach to risk prediction, prevention and treatment.
引用
- Van Craenenbroeck AH, Chinnappa S, Dounousi E, et al. New kidneys, old risks: cardiovascular challenges after transplantation. Nephrol Dial Transplant. 2026. PMID: 41206563. doi:10.1093/ndt/gfaf239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。